FDA Tells RegeneRx It Needs 3rd Phase III Trial On RGN-259 For Dry Eye Syndrome

 
• By Sten Stovall
Eye
ReGenTree will begin the third Phase III trial, ARISE-3, this year. • Source: Shutterstock

More from New Products

More from Scrip